| Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants (NCT07670897) | Gan & Lee Pharmaceuticals. | 2026-07-01 |
| A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer (NCT07468396) | Gan & Lee Pharmaceuticals. | 2026-04-30 |
| Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy (NCT07493057) | Gan & Lee Pharmaceuticals. | 2026-04-27 |
| Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (NCT07387003) | Gan & Lee Pharmaceuticals. | 2026-04-10 |
| Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes (NCT07527078) | Gan & Lee Pharmaceuticals. | 2026-04-07 |
| A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects (NCT07334496) | Gan & Lee Pharmaceuticals. | 2026-03-09 |
| Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss (NCT07292441) | Gan & Lee Pharmaceuticals. | 2026-01-22 |
| Bioequivalence Study of GZR18 Injection Before and After CMC Change (NCT07355738) | Gan & Lee Pharmaceuticals. | 2026-01-09 |
| Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (NCT07128888) | Gan & Lee Pharmaceuticals. | 2025-11-17 |
| Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment (NCT07193147) | Gan & Lee Pharmaceuticals. | 2025-10-20 |
| A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin (NCT07165223) | Gan & Lee Pharmaceuticals. | 2025-10-17 |
| Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function (NCT07144098) | Gan & Lee Pharmaceuticals. | 2025-08-12 |
| A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects (NCT06974487) | Gan & Lee Pharmaceuticals. | 2025-05-08 |
| The Study of [14C] GZR18 (NCT07119450) | Gan & Lee Pharmaceuticals. | 2025-05-07 |
| Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function (NCT07141030) | Gan & Lee Pharmaceuticals. | 2025-04-11 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin (NCT06767761) | Gan & Lee Pharmaceuticals. | 2025-02-18 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) (NCT06767735) | Gan & Lee Pharmaceuticals. | 2025-02-17 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin (NCT06767748) | Gan & Lee Pharmaceuticals. | 2025-02-15 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus (NCT06778967) | Gan & Lee Pharmaceuticals. | 2025-02-13 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise (NCT06777238) | Gan & Lee Pharmaceuticals. | 2025-01-16 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects (NCT06728124) | Gan & Lee Pharmaceuticals. | 2024-12-30 |
| A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid (NCT06780410) | Gan & Lee Pharmaceuticals. | 2024-12-20 |